Ansell Limited sells condom business: Here’s what you need to know

Ansell Limited (ASX: ANN) made a big splash this morning when it announced it would sell its Sexual Wellness business, whilst also announcing a major share-buyback program. As a result, the Ansell share price rose a little over 3% shortly after the market opened.

Ansell describes itself as a global leader in protection solutions, saying that its vision is “to create a world where people can enjoy optimal protection against the risk they are exposed to”. Thus, they sell products such as industrial gloves and body protection, rubber gloves and medical solutions, as well as condoms and other personal products in various regions around the world.

Sexual Wellness Divestiture

The company announced this morning that it has already executed a binding agreement to sell the Sexual Wellness division for US$600 million ($800 million) to Humanwell Healthcare Group and CITIC Capital China Partners. Ansell said that the sale includes all of Ansell’s condom and lubricant business and manufacturing sites, although it will retain its Medical and Sexual Wellness joint venture in India.

It’s worth taking a look at how the division stacked up against the company’s other segments in 2016:

Sales (US$ million) EBIT (US$ million) EBIT Margin %
Industrial 654.8 89.0 13.6%
Medical 396.3 52.3 13.2%
Single Use 301.7 64.6 21.4%
Sexual Wellness 220.0 31.0 14.1%
Total 1,572.8 236.9 15.1%

Sexual Wellness is the group’s smallest division. In 2016, the division generated US$220 million in sales, representing 14% of the group’s sales, up 1.4% on 2015 or 8.2% on a constant currency basis. That compares to sales of US$229.7 million achieved back in 2013.

It also generated $31 million in earnings before interest and tax (EBIT), up 41% on a constant currency basis, representing 13% of the group’s operating earnings and an EBIT margin of 14.1%. That makes it the group’s second-most profitable business division, behind ‘Single Use’.

Indeed, Ansell first highlighted the potential for a divestiture of the segment in August last year as part of an existing portfolio review. At the time, it also noted it would consider opportunities to enhance its position in the Industrial and Medical businesses with value-enhancing acquisitions.

Share Buyback Program

In the announcement this morning, Ansell also flagged a new on-market buyback program which could see the company repurchase up to 10% of the group’s issued capital over the next 12 months. That would imply a buyback of up to $356 million in shares.

However, investors need to keep in mind that Ansell is under no obligation to actually fulfil that buyback program. Whether it does largely depends on the share price at the time (it’s unlikely to buy them if it believes they’re too expensive) and on market conditions. Meanwhile, it could also elect to spend the money on other strategic acquisitions, as flagged above.

With today’s gain, the Ansell share price has now risen around 33% over the past 12 months. The company has guided for earnings per share in the range of US$1.00 to US$1.12 ($1.33 to $1.49, or an average of $1.41), putting the shares on a forward price-earnings ratio of around 17.6x.

Here Are the Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Ryan Newman has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.